Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Halyard Health (NYSE:HYH) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 12,691 shares of the medical instruments supplier’s stock, valued at approximately $727,000.

Several other hedge funds also recently added to or reduced their stakes in HYH. LPL Financial LLC grew its position in Halyard Health by 82.8% during the 1st quarter. LPL Financial LLC now owns 8,168 shares of the medical instruments supplier’s stock worth $376,000 after acquiring an additional 3,699 shares during the last quarter. BlackRock Inc. grew its position in Halyard Health by 1.1% during the 1st quarter. BlackRock Inc. now owns 4,995,130 shares of the medical instruments supplier’s stock worth $230,176,000 after acquiring an additional 52,167 shares during the last quarter. FIL Ltd grew its position in Halyard Health by 27.3% during the 1st quarter. FIL Ltd now owns 59,622 shares of the medical instruments supplier’s stock worth $2,747,000 after acquiring an additional 12,798 shares during the last quarter. OMERS ADMINISTRATION Corp grew its position in Halyard Health by 46.1% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 13,000 shares of the medical instruments supplier’s stock worth $599,000 after acquiring an additional 4,100 shares during the last quarter. Finally, Sei Investments Co. grew its position in Halyard Health by 15.3% during the 1st quarter. Sei Investments Co. now owns 25,766 shares of the medical instruments supplier’s stock worth $1,187,000 after acquiring an additional 3,418 shares during the last quarter. Institutional investors own 90.24% of the company’s stock.

A number of equities research analysts recently commented on HYH shares. Zacks Investment Research lowered Halyard Health from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 27th. KeyCorp increased their price target on Halyard Health from $61.00 to $62.00 and gave the stock an “overweight” rating in a research report on Thursday, May 3rd. Morgan Stanley increased their price objective on Halyard Health from $48.50 to $52.00 and gave the company an “underweight” rating in a research report on Thursday, May 3rd. Stifel Nicolaus increased their price objective on Halyard Health from $52.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. Finally, Deutsche Bank increased their price objective on Halyard Health from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Halyard Health has a consensus rating of “Buy” and an average target price of $59.80.

Shares of HYH opened at $57.25 on Wednesday. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 3.68 and a beta of 1.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.96 and a current ratio of 3.22. Halyard Health has a 52 week low of $38.22 and a 52 week high of $61.52.

Halyard Health Profile

Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

See Also: Investing in Dividend Stocks

Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health (NYSE:HYH).

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.